source
- Novartis CEO says shareholders remain supportive despite recent trial setbacksNovartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
- Pfizer signs $2.6 billion deal with China's Starna to acquire in vivo CAR-T programs for autoimmune diseasesPfizer announced a $2.6 billion agreement with Chinese biotech Starna Therapeutics to obtain rights to three preclinical in vivo CAR-T candidates aimed at autoimmune diseases. The deal includes a…